MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ: MLTX (MoonLake Immunotherapeutics)

Last update: 22 hours ago

11.74

-0.76 (-6.08%)

Previous Close 12.50
Volume 778,485
Price / Book 2.79
52 Weeks Range
9.46 (-19%) — 23.29 (98%)
Diluted EPS (TTM) -2.30
Total Debt/Equity (MRQ) 18.32%
Current Ratio (MRQ) 21.11
Operating Cash Flow (TTM) -139.78 M
Levered Free Cash Flow (TTM) -102.40 M
Return on Assets (TTM) -19.85%
Return on Equity (TTM) -30.64%

AIStockmoo Score

-0.2
Value 30% -0.5
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Earns below its cost of capital. Returns on capital rising. info
Timing 30% -3.0
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.3
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Smart Money 20% 3.6
Insider Activity info NA
Institutions net +19.19% of shares in their latest 13F filings: 103 holders increased, 83 decreased (quarter to 30 Sep 2026). info
Short interest -23.4% from 31 Aug to 30 Oct 2026, 2.9 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Not in score
Price is low against its 52-week average. Up over 5 years. info
Short-term momentum rising. info
Price is between support and resistance. info
Final Score -0.24

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock MoonLake Immunotherapeutics Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MLTX - - - 2.79
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
VKTX - - - 6.33
VSTM - - - 76.50
CRMD - - - 0.800

Select this tab to load the latest available analysis.

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 15.34%
% Held by Institutions 96.70%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 94.73%

Positions Holders Shares
Increased 103 21,066,532
Decreased 83 10,045,773
New 38 8,512,207
Sold out 31 3,220,864

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 5,473,842 2.9
15 Oct 2026 7,833,997 4.1
30 Sep 2026 8,048,665 4.2
15 Sep 2026 8,947,906 6.1
31 Aug 2026 7,144,513 6.7
14 Aug 2026 6,819,147 4.2

FINRA short interest via Nasdaq, reported twice a month.

2 Positive 1 Negative 2 Neutral
Date Type Details
12 Nov 2026 Yahoo Finance MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its…
11 Nov 2026 Yahoo Finance MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments.
10 Nov 2026 Yahoo Finance Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with…
09 Nov 2026 Yahoo Finance MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
MoonLake Immunotherapeutics reported third quarter 2026 results with a net loss of US$79.55 million and basic and diluted loss per share of US$0.93, and a nine month 2026 net loss of US$211.06 million with basic and diluted loss per share of US$2.74. The narrower quarterly loss per share compared…
04 Nov 2026 Yahoo Finance MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercializationPositive Week 16 results from…
25 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
Recent Performance Snapshot MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after recent trading saw the share price close at $11.85. Performance has been mixed across timeframes and marked by sharp moves over the past 3 months. That recent jump in MoonLake Immunotherapeutics, with a…
24 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
MoonLake Immunotherapeutics has seen sharp swings in its share price in recent years, which puts fresh focus on what investors are really paying for on the balance sheet. With the stock last closing at US$11.85, the live question is how that market tag lines up with the company’s book value. The…
22 Oct 2026 Yahoo Finance AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23…
22 Oct 2026 Yahoo Finance MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelming.
16 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
MoonLake Immunotherapeutics (MLTX) made a "reasonably solid" case for the approvability of sonelokim…
05 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo…
21 Sep 2026 Yahoo Finance Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics)…
11 Sep 2026 Yahoo Finance MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
Show more

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria